TransMedics Group (NASDAQ:TMDX) Director David Weill Sells 3,571 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill sold 3,571 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the sale, the director owned 12,134 shares in the company, valued at approximately $1,781,513.88. The trade was a 22.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

TransMedics Group Stock Down 7.3%

Shares of TransMedics Group stock traded down $10.27 on Friday, reaching $129.80. The company’s stock had a trading volume of 1,079,448 shares, compared to its average volume of 822,516. TransMedics Group, Inc. has a 52 week low of $62.23 and a 52 week high of $156.00. The firm’s fifty day simple moving average is $135.35 and its two-hundred day simple moving average is $126.90. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

TMDX has been the subject of several research reports. Oppenheimer upped their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Morgan Stanley boosted their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Canaccord Genuity Group increased their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Piper Sandler lifted their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $150.67.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Intech Investment Management LLC raised its position in shares of TransMedics Group by 28.9% in the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after purchasing an additional 7,713 shares during the last quarter. Nordea Investment Management AB acquired a new position in TransMedics Group during the third quarter valued at $4,070,000. Peregrine Capital Management LLC boosted its holdings in TransMedics Group by 16.5% in the third quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after purchasing an additional 9,676 shares during the last quarter. Intrust Bank NA purchased a new stake in TransMedics Group in the second quarter valued at $747,000. Finally, Lisanti Capital Growth LLC grew its position in TransMedics Group by 62.0% during the 3rd quarter. Lisanti Capital Growth LLC now owns 56,901 shares of the company’s stock worth $6,384,000 after purchasing an additional 21,771 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.